Literature DB >> 19001534

Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis.

Y Yuan1, Z-X Gu, W-S Wei.   

Abstract

BACKGROUND AND
PURPOSE: Patients with mild cognitive impairment (MCI) are at risk for developing Alzheimer disease (AD). To diagnose AD at an early stage, one must develop highly specific and sensitive tools to identify it among at-risk subjects. The purpose of this study was to evaluate and compare the ability of fluorodeoxyglucose-positron-emission tomography (FDG-PET), single-photon emission tomography (SPECT), and structural MR imaging to predict conversion to AD in patients with MCI.
MATERIALS AND METHODS: Relevant studies were identified with MEDLINE from January 1990 to April 2008. Meta-analysis and meta-regression were done on the diagnostic performance data for each technique from eligible studies. We estimated and compared the weighted summary sensitivities, specificities, likelihood ratios (LRs), and summary receiver operating characteristic curves of each imaging technique.
RESULTS: Twenty-four eligible studies were included, with a total of 1112 patients. FDG-PET performed statistically better in LR+ and odds ratio (OR), whereas no statistical difference was found in pooled sensitivity, specificity, and LR- for each technique. No statistical difference was confirmed between SPECT and MR imaging. The Q* index estimates for FDG-PET, SPECT, and structural MR imaging were respectively 0.86, 0.75, and 0.76. In meta-regression, statistical significance was found only between technique and log OR, with a regression coefficient of -0.575.
CONCLUSIONS: This meta-analysis showed that FDG-PET performs slightly better than SPECT and structural MR imaging in the prediction of conversion to AD in patients with MCI; parallel performance was found between SPECT and MR imaging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001534     DOI: 10.3174/ajnr.A1357

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  47 in total

Review 1.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

Review 2.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 3.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

4.  Cerebral blood flow MRI in the nondemented elderly is not predictive of post-operative delirium but is correlated with cognitive performance.

Authors:  Tammy T Hshieh; Weiying Dai; Michele Cavallari; Charles Rg Guttmann; Dominik S Meier; Eva M Schmitt; Bradford C Dickerson; Daniel Z Press; Edward R Marcantonio; Richard N Jones; Yun Ray Gou; Thomas G Travison; Tamara G Fong; Long Ngo; Sharon K Inouye; David C Alsop
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

5.  Automated MRI measures predict progression to Alzheimer's disease.

Authors:  Rahul S Desikan; Howard J Cabral; Fabio Settecase; Christopher P Hess; William P Dillon; Christine M Glastonbury; Michael W Weiner; Nicholas J Schmansky; David H Salat; Bruce Fischl
Journal:  Neurobiol Aging       Date:  2010-06-08       Impact factor: 4.673

6.  Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning.

Authors:  Simon F Eskildsen; Pierrick Coupé; Daniel García-Lorenzo; Vladimir Fonov; Jens C Pruessner; D Louis Collins
Journal:  Neuroimage       Date:  2012-10-02       Impact factor: 6.556

7.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

9.  Role of structural MRI in Alzheimer's disease.

Authors:  Prashanthi Vemuri; Clifford R Jack
Journal:  Alzheimers Res Ther       Date:  2010-08-31       Impact factor: 6.982

10.  Early marker for Alzheimer's disease: hippocampus T1rho (T(1rho)) estimation.

Authors:  Mohammad Haris; Erin McArdle; Matthew Fenty; Anup Singh; Christos Davatzikos; John Q Trojanowski; Elias R Melhem; Christopher M Clark; Arijitt Borthakur
Journal:  J Magn Reson Imaging       Date:  2009-05       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.